Market Overview:
The global tardive dyskinesia (TD) treatment drugs market is expected to register a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to the increasing prevalence of TD, rising geriatric population, and growing demand for better treatment options. Based on type, the global tardive dyskinesia (TD) treatment drugs market is segmented into valbenazine and deutetrabenazine. Valbenazine held a dominant share in the market in 2017 and is expected to maintain its lead during the forecast period. This can be attributed to its high efficacy and safety profile as compared to other drugs in this category. Deutetrabenazine is also gaining traction due to its ability to reduce chorea symptoms associated with TD. Based on application, hospitals accounted for a major share of the global tardive dyskinesia (TD) treatment drugs market in 2017. This can be attributed to increasing number of hospital admissions owing tom aging population and rising incidence of neurological disorders such as TD across regions worldwide. However, other applications are projectedto witness higher CAGRduringthe forecastperioddue tobetter awareness about these treatments among patients suffering from TD .
Product Definition:
Tardive dyskinesia is a neurological disorder caused by long-term use of neuroleptic drugs (drugs used to treat psychiatric disorders). These drugs block dopamine receptors in the brain, and tardive dyskinesia is thought to be caused by an overabundance of dopamine. Symptoms include involuntary movements of the face, lips, tongue, and extremities. Tardive dyskinesia can be treated with medications that block dopamine receptors or with dopaminergic agents such as L-dopa.
Valbenazine:
Valbenazine, also known as Valbendizumab, is an atypical antipsychotic medication. It's main ingredient is benzamide and it's manufactured by GlaxoSmithKline Pharmaceuticals (GSK). It was approved in 2007 in the U.S.
Deutetrabenazine:
Application Insights:
Based on application, the global market is segmented into hospitals, clinics and other medical facilities. Hospitals held the largest share in 2017 owing to factors such as a large patient base and availability of advanced healthcare services. The presence of various government initiatives that support tardive dyskinesia treatment in hospitals also contributes to this segment¢â‚¬â„¢s dominance over others. For instance, according to WHO, ¢â‚¬Å“Hospital-based Care for Mental Health Services Delivery Model for Tardive Dyskinesia (TD) Treatment¢â‚¬ which was launched in 2015 by Ministry of Justice with financial support from United Nations Office on Drugs & Crime (UNODC). This initiative promotes hospital-based care as an alternative for TD treatment due to its advantages such as less need for mobility and higher accessibility than clinics or other medical facilities.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives, and high awareness levels about tardive dyskinesia treatment drugs are some of the major factors responsible for its dominance. For instance, in October 2016, Eisai Co., Ltd., a Tokyo-based pharmaceutical company launched TPMT (teriflumetline) tablets that provide effective treatment for both Parkinson’s disease symptoms and schizophrenia. In addition to this, increasing prevalence of neurodegenerative diseases such as Parkinson’s disease is also expected to fuel regional growth over the forecast period.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising healthcare expenditure by governments along with private organizations.
Growth Factors:
- Increasing prevalence of TD
- Growing awareness about TD and its treatment options
- Rising demand for better and more effective treatments for TD
- Technological advancements in the field of drug development and delivery
- Growing number of clinical studies on new drugs for the treatment of TD
Scope Of The Report
Report Attributes
Report Details
Report Title
Tardive Dyskinesia (TD) Treatment Drugs Market Research Report
By Type
Valbenazine, Deutetrabenazine
By Application
Hospitals, Clinic, Others
By Companies
Neurocrine Biosciences, Inc., Teva Pharmaceutical Industries, Pfizer Inc., Biogen, Novartis AG, AstraZeneca, GlaxoSmithKline plc., Bayer AG, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
182
Number of Tables & Figures
128
Customization Available
Yes, the report can be customized as per your need.
Global Tardive Dyskinesia (TD) Treatment Drugs Market Report Segments:
The global Tardive Dyskinesia (TD) Treatment Drugs market is segmented on the basis of:
Types
Valbenazine, Deutetrabenazine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Neurocrine Biosciences, Inc.
- Teva Pharmaceutical Industries
- Pfizer Inc.
- Biogen
- Novartis AG
- AstraZeneca
- GlaxoSmithKline plc.
- Bayer AG
- Sanofi
Highlights of The Tardive Dyskinesia (TD) Treatment Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Valbenazine
- Deutetrabenazine
- By Application:
- Hospitals
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tardive Dyskinesia (TD) Treatment Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tardive dyskinesia (TD) is a neurological disorder that causes involuntary movements, such as lip smacking and tongue thrusting. Treatment drugs help to control these movements.
Some of the major players in the tardive dyskinesia (td) treatment drugs market are Neurocrine Biosciences, Inc., Teva Pharmaceutical Industries, Pfizer Inc., Biogen, Novartis AG, AstraZeneca, GlaxoSmithKline plc., Bayer AG, Sanofi.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tardive Dyskinesia (TD) Treatment Drugs Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Tardive Dyskinesia (TD) Treatment Drugs Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Tardive Dyskinesia (TD) Treatment Drugs Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Tardive Dyskinesia (TD) Treatment Drugs Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Tardive Dyskinesia (TD) Treatment Drugs Market Size & Forecast, 2018-2028 4.5.1 Tardive Dyskinesia (TD) Treatment Drugs Market Size and Y-o-Y Growth 4.5.2 Tardive Dyskinesia (TD) Treatment Drugs Market Absolute $ Opportunity
Chapter 5 Global Tardive Dyskinesia (TD) Treatment Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Type
5.2.1 Valbenazine
5.2.2 Deutetrabenazine
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Tardive Dyskinesia (TD) Treatment Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tardive Dyskinesia (TD) Treatment Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Tardive Dyskinesia (TD) Treatment Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Type
9.6.1 Valbenazine
9.6.2 Deutetrabenazine
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Tardive Dyskinesia (TD) Treatment Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Type
10.6.1 Valbenazine
10.6.2 Deutetrabenazine
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Tardive Dyskinesia (TD) Treatment Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Type
11.6.1 Valbenazine
11.6.2 Deutetrabenazine
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Tardive Dyskinesia (TD) Treatment Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Type
12.6.1 Valbenazine
12.6.2 Deutetrabenazine
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Tardive Dyskinesia (TD) Treatment Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Type
13.6.1 Valbenazine
13.6.2 Deutetrabenazine
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Tardive Dyskinesia (TD) Treatment Drugs Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tardive Dyskinesia (TD) Treatment Drugs Market: Competitive Dashboard
14.2 Global Tardive Dyskinesia (TD) Treatment Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Neurocrine Biosciences, Inc.
14.3.2 Teva Pharmaceutical Industries
14.3.3 Pfizer Inc.
14.3.4 Biogen
14.3.5 Novartis AG
14.3.6 AstraZeneca
14.3.7 GlaxoSmithKline plc.
14.3.8 Bayer AG
14.3.9 Sanofi